MS & PHD STUDENTS

Craig Fisher, PhD

Degree: 
PhD
Program: 
Pharmacology and Toxicology
Track: 
Pharmacology and Toxicology
Dissertation Title: 
“Non-Alcoholic Fatty Liver Disease Alters the Three Stages of Hepatic Drug Management”

Alumnus
Year Graduated: 2009
Career Type: Industry
Scientist II, Investigational Toxicology Millennium: The Tekeda Oncology Co.

Academic & Professional Updates
I am currently working in Boston, MA working as an investigative toxicologist in the Drug Safety Evaluation group of at Millennium: The Takeda Oncology Company. As an investigative toxicologist, I am responsible for identifying the molecular mechanisms by which Millennium oncology drugs cause systemic or organ specific toxicity. By identifying the mechanism by which a specific compound causes toxicity, the Drug Safety Evaluation group can determine whether this is a complication that can be ameliorated by changes in the compound structure, dosing regiment, drug formulation, route of administration or possibly co administration of another medication. If in fact a drug’s toxicity is dose limiting and can not be avoided by one of the methods mentioned above, our studies provide data that will be used in the ultimate decision of whether to continue its development through the Millennium drug pipeline.

Publications
1. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 alterations in humans with progressive stages of non-alcoholic fatty liver disease. Submitted to Gut (Jan 2009).
2. Fisher CD, Lickteig AJ, Augustine LM, Besselsen DG, Erickson RP, and Cherrington NJ. Nonalcoholic fatty liver disease results in decreased uptake transporter expression and BSP clearance in rats. Accepted with revisions European Journal of Pharmacology (Dec 2008).
3. Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, and Cherrington NJ. Drug metabolism enzyme induction pathways in nonalcoholic steatohepatitis (NASH). Arch Toxicol. 2008 May 17.
4. Merrell MD, Jackson JP, Augustine LM, Fisher CD, Slitt AL, Maher JM, Zhang Y, Huang W, Moore DD, Klaassen CD, and Cherrington NJ. The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metab Dispos. 2008 May 12.
5. Augustine LM, Fisher CD, Aleksunes LM, Slitt AL, and Cherrington NJ. Gender divergent Nqo1 expression in Sprague Dawley and August Copenhagen x Irish rats. J Biochem Mol Toxicol. 2008;22(2):93-100.
6. Lickteig AJ, Fisher CD, Augustine LM, Cherrington NJ. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol. 2007;21(4):216-20.
7. Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, Cherrington NJ.  Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos. 2007 Oct;35(10):1970-8.
8. Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman- McKeeman LD, Cherrington NJ. Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos. 2007 Jun;35(6):995-1000.  
9. Slitt AL, Cherrington NJ, Fisher CD, Negishi M, Klaassen CD. Induction of genes for metabolism and transport by trans-stilbene oxide in livers of Sprague-Dawley and Wistar-Kyoto rats. Drug Metab Dispos. 2006 Jul;34(7):1190-7.
Originally posted: August 21, 2014
Last updated: October 8, 2015
Want to update? Contact Webmaster
Share This